What the term means in practice
For many searchers, a Boston spinal cord stimulator means a Boston Scientific spinal cord stimulation system, often from the WaveWriter family. These prescription implantable neuromodulation devices are used to help manage chronic, difficult-to-treat pain of the trunk and limbs in carefully selected patients. The device itself is only part of the story. FDA-cleared indications, clinical evidence, MRI conditions, and safety communications all affect how these systems are selected and managed. FDA records show notable indication additions in 2023 and 2024, while a 2026 FDA recall notice for unused Infinion CX leads added a practical safety checkpoint for hospitals and clinicians. Patients should use this information as background for discussion with a pain specialist, not as individual medical advice.
Spinal cord stimulation, or SCS, is usually considered after less invasive therapies have not provided adequate relief. It does not remove the underlying cause of pain. Instead, implanted leads deliver controlled electrical pulses near the spinal cord with the goal of changing how pain signals are perceived. The implantable pulse generator is placed under the skin and connected to one or more leads. A clinician programs the therapy, and the patient uses a controller to turn therapy on or off or adjust preset options.
For readers comparing device categories, our Spinal Devices section covers related implantable and interventional technologies.
How Boston Scientific SCS systems are built
FDA summaries describe Boston Scientific SCS systems as totally implanted devices that deliver stimulation to the dorsal column of the spinal cord. The main implanted components are the implantable pulse generator, percutaneous or surgical leads, lead extensions when needed, and anchoring components. External components may include a trial stimulator, a clinician programmer, a remote control, and a charger for rechargeable models.
The WaveWriter Alpha and WaveWriter Alpha Prime systems sit within a broader Boston Scientific portfolio that also includes Precision, Precision Spectra, Precision Novi, Precision Montage MRI, and Spectra WaveWriter systems. The WaveWriter Alpha family includes rechargeable and non-rechargeable implantable pulse generator options. Boston Scientific describes the system as supporting multiple programming approaches, including paresthesia-based and paresthesia-free therapy options. The exact configuration matters because MRI eligibility, battery management, lead compatibility, and programming features can differ by model and implanted components.
A short trial is commonly used before permanent implantation. During the trial, temporary leads are connected to an external stimulator so the patient and clinician can judge whether therapy provides meaningful relief. If the trial does not provide effective pain relief, Boston Scientific labeling and FDA summaries list failed trial stimulation as a contraindication for permanent SCS therapy.
FDA indication timeline and what changed
The clearest way to read the current device landscape is to separate long-standing SCS indications from later FDA supplements. The table below summarizes key dates from FDA records and public FDA summaries.
| Date | FDA or safety event | Why it matters |
|---|---|---|
| April 27, 2004 | Original PMA P030017 approval for Boston Scientific SCS technology | Established the base approval pathway for use as an aid in managing chronic intractable pain of the trunk and limbs. |
| December 1, 2020 | FDA PMA supplement decision for WaveWriter Alpha SCS System | Brought the WaveWriter Alpha portfolio into the U.S. approval pathway. |
| October 5, 2023 | Expanded indication for diabetic peripheral neuropathy of the lower extremities for paresthesia-based stimulation | Added a specific painful diabetic neuropathy use case, with important patient-selection and infection-risk considerations. |
| February 5, 2024 | Expanded indication for chronic intractable low back and leg pain without prior back surgery | Extended eligible use beyond patients with prior lumbar surgery, based on the SOLIS study. |
| June 17, 2026 and FDA notice in 2026 | Boston Scientific customer letter and FDA recall notice for unused Infinion CX Lead Kits | Created a safety and inventory-management issue for affected unused lead kits, while FDA stated the action did not affect already implanted devices. |
The 2024 FDA expansion is particularly relevant for readers who still associate SCS mainly with failed back surgery syndrome. FDA materials state that Spectra WaveWriter, WaveWriter Alpha, and WaveWriter Alpha Prime systems are also indicated as an aid in managing chronic intractable unilateral or bilateral low back and leg pain without prior back surgery. That does not mean every patient with back pain is a candidate. The FDA-reviewed study population had defined inclusion and exclusion criteria, including chronic low back pain with or without leg pain for at least six months and prior documented pain management care.
What conditions are included in labeling
FDA summaries list Boston Scientific SCS systems as an aid in managing chronic intractable pain of the trunk and limbs, including unilateral or bilateral pain associated with several conditions. These include failed back surgery syndrome, complex regional pain syndrome types I and II, diabetic peripheral neuropathy of the lower extremities, intractable low back pain and leg pain, radicular pain syndrome, radiculopathies related to failed back syndrome or herniated disc, epidural fibrosis, degenerative disc disease when herniated disc pain is refractory to conservative and surgical interventions, arachnoiditis, and multiple back surgeries.
The same FDA materials identify situations where permanent SCS therapy should not be used. These include patients who cannot operate the system, patients who failed trial stimulation by not receiving effective relief, patients who are poor surgical candidates, and pregnancy. Boston Scientific safety information also notes that pediatric safety and effectiveness have not been established.
The wording aid in management is important. SCS is not presented as a cure, a first-line treatment, or a guaranteed alternative to surgery. It is one option in a broader pain-management pathway that may also include medication management, physical therapy, psychological therapies, TENS, injections, and other interventional or surgical approaches. The clinical decision depends on pain diagnosis, anatomy, prior treatments, surgical risk, mental health screening, expectations, and the patient’s ability to manage an implanted device.
Clinical evidence behind the newer low back pain indication
The FDA decision for the 2024 no-prior-back-surgery indication relied on the SOLIS study, a prospective, multicenter, randomized controlled trial in the United States. The study compared SCS using Boston Scientific WaveWriter systems with conventional medical management in patients with chronic low back and/or leg pain who had not undergone spinal surgery. FDA documents state that patients were treated between March 26, 2021 and May 17, 2023, at 23 U.S. investigational sites.
In the interim analysis described by FDA, 212 subjects had provided informed consent, 115 were randomized, and a prespecified cohort of 60 activated subjects completed the three-month post-activation visit. The primary endpoint was the proportion of subjects with at least a 50% reduction from baseline in average overall low back and/or leg pain at three months, with no increase in baseline average daily opioid medication used for pain.
The study met its primary endpoint. FDA summaries report an 87.5% responder rate with no opioid increase in the SCS group compared with 8.3% in the conventional medical management group at three months, with statistical significance reported as p less than 0.0001. Additional data documented sustained results at six and twelve months, although FDA also noted that crossover of control-group patients affected longer-term between-group comparisons.
These results are meaningful, but they need context. The FDA review was based on a selected trial population, an interim analysis, and protocol-defined endpoints. Study participants had severe baseline pain and disability, with mean overall pain of 7.6 on a 0 to 10 scale and mean Oswestry Disability Index score of 56.2 in the 60 treatment-activated subjects. The findings support an expanded indication; they do not predict individual outcomes for every patient with chronic back pain.
Diabetic peripheral neuropathy evidence and added risks
The 2023 FDA expansion for diabetic peripheral neuropathy of the lower extremities was limited to paresthesia-based stimulation. FDA safety and effectiveness documents state that the evidence included a systematic review of published clinical literature, with primary evidence from two randomized controlled trials in painful diabetic peripheral neuropathy. FDA also reviewed additional safety evidence, including data from 300 subjects treated with SCS for diabetic peripheral neuropathy and 2,235 diabetic patients across four studies that reported on SCS, including infection-focused studies.
The benefit-risk discussion in FDA materials is balanced. Reported benefits included clinically meaningful pain reduction in many implanted subjects, but diabetic patients had additional risks. FDA materials identify infection, delayed wound healing, cardiovascular events, dural puncture with subsequent subdural hematoma, and glycemic fluctuations as risks that require careful patient selection and monitoring. In practice, this makes coordination among pain specialists, diabetes care clinicians, and surgical teams especially important. See also: Implants.
MRI access is conditional, not automatic
MRI compatibility is one of the most common questions about any implanted spinal cord stimulator. Boston Scientific describes WaveWriter Alpha and WaveWriter Alpha Prime systems as MR conditional under defined conditions. FDA and Boston Scientific materials distinguish this from a general claim that a patient can receive any MRI scan at any imaging center.
MR conditional means a scan may be allowed only when the implanted system, lead configuration, scanner type, body region, device settings, battery state, and procedural steps meet the applicable ImageReady MRI guidelines. Boston Scientific patient guidance states that patients should check their device medical ID card and confirm MRI conditions before a scan. Some older systems may have limited or no MRI capability, and mixed-component systems can add further restrictions.
This distinction matters for care planning. A patient who expects future orthopedic, neurologic, or abdominal imaging should discuss MRI needs before implantation. Clinicians should verify the exact model numbers and lead configuration, not just the brand name. The practical question is not whether the device is MRI safe in a broad sense, but whether a specific patient with a specific implanted system can undergo a specific MRI protocol under the required conditions.
The 2026 Infinion CX lead recall in context
In 2026, the FDA published a recall notice involving Boston Scientific Infinion CX Lead Kits in 50 cm and 70 cm versions. The FDA described the recall as involving removal of unused devices from where they are used or sold and identified it as the most serious type of recall. FDA materials state that Boston Scientific sent affected customers a letter on June 17, 2026, recommending that affected products be stopped from further use or distribution, segregated, returned, and communicated to relevant healthcare professionals and organizations.
The reason for recall was mechanical stress at the anchor site that could lead to high impedance measurements or lead fractures. FDA stated that abnormal impedance may lead to inadequate stimulation or additional intervention, including lead explant and replacement. As of May 27, 2026, Boston Scientific had reported 1,081 serious injuries and no deaths associated with the issue.
Two clarifications are important. First, FDA stated that the action did not affect devices that had already been implanted. Second, the recall involved specific Infinion CX Lead Kits, not every Boston Scientific spinal cord stimulator system. Patients with an implanted system should not assume their device must be removed because of a recall headline. They should check their device card, contact their implanting clinician or device support pathway, and seek medical attention if stimulation changes, pain control suddenly worsens, or new neurologic symptoms occur.
Patient selection remains the limiting factor
Device features are only one part of SCS outcomes. A 2023 consensus guideline article in Regional Anesthesia and Pain Medicine, summarized in PubMed, emphasized patient selection and trial stimulation for chronic non-cancer pain. The recommendations included performing an SCS trial before definitive implantation except in anginal pain, screening all patients with an objective validated instrument for psychosocial factors including depression, and using clinician judgment based on individual patient considerations and preferences.
That aligns with the practical limitations described in FDA summaries. SCS can reduce pain for selected patients, but some patients experience inadequate relief, loss of effect over time, uncomfortable stimulation, lead migration, infection, device discomfort, hardware issues, or need for revision. The best candidate is not defined by a brand name alone. Candidacy depends on a documented pain diagnosis, realistic goals, an acceptable surgical risk profile, successful trial stimulation, and the ability to operate and maintain the system.
Questions to ask before implantation or revision
- Which exact Boston Scientific system, pulse generator, and leads are being considered?
- Is the intended therapy paresthesia-based, paresthesia-free, or a combination of programs?
- Which labeled indication applies to my diagnosis?
- What trial result would count as success before permanent implantation?
- How will future MRI needs be handled with this exact system and lead configuration?
- Is any component affected by a recall, field action, or MRI restriction?
- What are the risks of infection, lead migration, loss of relief, battery depletion, and revision surgery in my situation?
- Who manages programming changes after implantation, and how quickly can support be accessed if relief changes?
Frequently asked questions
Is a Boston spinal cord stimulator the same as WaveWriter Alpha?
Not always. The phrase is commonly used by patients to mean a Boston Scientific spinal cord stimulator. WaveWriter Alpha is one Boston Scientific SCS family, but the company has several SCS systems and legacy platforms. The exact implanted model and lead configuration determine many practical details.
Can a Boston Scientific SCS cure chronic back pain?
No. FDA labeling describes SCS as an aid in managing chronic intractable pain. It may reduce pain in selected patients, but it does not cure the underlying spine, nerve, or metabolic condition that contributes to pain.
Does MR conditional mean any MRI is allowed?
No. MR conditional means MRI may be performed only when specific device, component, scanner, programming, and procedural conditions are met. Patients should confirm eligibility using their device identification card and their clinician or device support team before scheduling imaging.
Does the 2026 Infinion CX recall mean implanted systems must be removed?
FDA stated that the recall action affected unused devices and did not affect devices already implanted. Patients should still verify their specific components and follow routine clinical follow-up, especially if stimulation becomes ineffective or symptoms change.
Who should decide whether SCS is appropriate?
A qualified pain specialist or neuromodulation team should evaluate candidacy. The decision typically includes diagnosis review, prior treatment history, imaging, psychological screening, trial stimulation results, medical risk assessment, and discussion of patient goals.
Bottom line
Boston Scientific spinal cord stimulator systems have a long FDA approval history and a broader current indication set than many patients may realize, including selected chronic low back and leg pain without prior back surgery and painful diabetic peripheral neuropathy of the lower extremities. At the same time, MRI access is conditional, patient selection is critical, and the 2026 Infinion CX lead recall shows why exact component identification matters. For clinicians and patients, the most reliable approach is to discuss the specific device model, indication, trial response, MRI needs, and safety profile before making treatment decisions.